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Background: The objective of this paper is to provide analytical research that supported the European Commission
in setting the global target of additional two healthy life years (HLY) at birth by 2020 in the EU on average, within
the European Innovation Partnership on Active and Healthy Ageing (the EIP on AHA). It produces a straightforward
analysis of HLY projections that helped the European Commission set a firm, politically sound, target. In order to
reach that goal, policy makers need to commit to redefining health priorities and goals and developing and
implementing relevant strategies and programmes.
Methods: The study computes a simple simulation of the HLY at birth based on three demographic scenarios:
compression of morbidity, expansion of morbidity and an intermediary scenario, the dynamic equilibrium, given the
expected 2.1 year gain in male and 1.6 in female life expectancy (LE) by 2020. Data on HLY and projections of life
expectancy were obtained from Eurostat and 2008 was taken as a baseline. For consistency and given data gaps,
EU27 average values of HLY were calculated.
Results: In the EU27 as a whole, the difference between LE and HLY in 2008 was nearly 15 years for men and
20 years for women. The developments of healthy life expectancies across the EU Member States (MSs) are even
more diverse that makes it difficult to model any robust EU level trends.
Under compression of morbidity, life expectancy and HLY would increase by 2020 on average by 2.1 and 2.0 years
for men and by 1.6 and 1.4 years for women respectively. The expected years with disability would remain
unchanged while the HLY/LE ratio would improve leading to a 0.5% gain for both genders. Under expansion of
morbidity, life expectancy would increase by 2.1 years for men and 1.4 years for women by 2020, while HLY would
remain unchanged and the expected years with disability would increase by 2.1 years and 1.6 years in women. This
would imply the deterioration of the HLY/LE ratio for both men and women generating a 2.2% and 1.4% loss of
health for men and women accordingly. Under dynamic equilibrium, the HLY would increase but to a lesser extent
as the rise in life expectancy. The HLY would increase by 1.6 and 1.2 years for men and women respectively. HLY/LE
ratio would remain unchanged for both men (+0.1%) and women. The study shows that the first scenario would
reduce the HLY gap between the EU MSs by 1.4 years in men and 1.2 years in women, the second would generate
no change, while the third one would reduce the gap by 0.9 years in men and increase it by 0.7 years in women.
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Conclusions: The results of the study triggered the political decision of setting the global target of 2 additional
HLY for the European Innovation Partnership on Active and Healthy Ageing to be achieved by 2020. It is a ‘grand’
goal but can be achieved. Statistics clearly show that EU countries characterise very different levels of health
progress, with a gap of 2 decades and diverging trends. With this in mind, the EU HLY target should be
complemented by national HLY targets for men and women, set by MSs.
Keywords: Healthy life years, Life expectancy, EU target, Compression, Expansion, Equilibrium, Disability, Morbidity,
Mortality, Healthy ageingBackground
Europe and many other countries in the world are cur-
rently facing increasingly complex and systemic societal
challenges. Due to health care advances, increased
wealth, improved wellbeing and living standards and bet-
ter diets life expectancy has increased dramatically [1]. It
is projected that between 2010 and 2060 the number of
Europeans aged over 65 will double, from 88 to 153 mil-
lion, whilst of those over 80 will nearly triple, from 24 to
62 million [2]. However, the increased longevity has not
always occurred in parallel with improved health and
quality of life [3]. As demonstrated in Figures 1 and 2
there has been a considerable gap between the extended
lifespan and the health expectancies. The ageing of the
population has dominated demographic change as one
of the most pertinent challenges of present and future.
In the light of the 1997 WHO Health Report, the
Director-General of WHO, Dr. Hiroshi Nakajima stated
that increased longevity without quality of life is an
empty prize. Health expectancy is more important than
life expectancy. The experience of the European Union
(EU) underlines the need to focus on health. Health and
healthy population is fundamental to the pursuit of
smart, sustainable and inclusive growth and better jobs.
More healthy life years mean a healthier workforce, and
less retirement on the grounds of ill health. It reduces
the burden on formal and informal care structures, lead-
ing to less strain on public finances and contributing to
the longer-term sustainability of the health and social
systems as the population ages [4].Figure 1 Life expectancy and healthy life years at birth among malesA range of factors impact the health status of ageing
populations therefore it cannot be simply assumed how
the healthy life expectancy (disability trends) will de-
velop in next decades. For example, rising obesity might
cause future increases in unhealthy lifespan, whereas
improvements in medical technologies such as joint
replacements can contribute towards lower disability
rates and higher healthy life years [2]. Assumptions,
therefore, cannot be made on the development of mor-
bidity and disability in the next decades, and on the
interaction between declining mortality, morbidity and
disability. Such uncertainty over health and disability
trends, combined with current data limitations, entails
the need to model different scenarios. For almost 50
years, there has been much debate over whether people
will live longer, healthier lives - the compression of morbid-
ity scenario, longer but more disabled/ ill-health lives - the
expansion of morbidity scenario, or something in between -
the dynamic equilibrium scenario [5,6]. In order to exam-
ine these different hypotheses, life expectancy per se is not
a sufficient indicator and needs to be completed with a
level of health status. Lifespan without or with disability/
ill-health defines the average number of years a person at
a certain age is expected to live in the particular health
condition. Health expectancies, combining life expectancy
with a concept of health - chronic disease, functional lim-
itations, activity restrictions, physical, mental or social
well-being - have become essential indicators of the health
of the ageing populations, where the quality of remaining
life is considered to be equally important as the quantitywithin the European Union and Member States, 2008.
Figure 2 Life expectancy and healthy life years at birth among females within the European Union and Member States, 2008.
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relevant health indicators [9]. Disability-free life expectan-
cies (DFLE) are commonly used as to refer to a relevant
measure of health of the population, and in particular of
older cohorts. For the sake of comparability of data and of
the more effective measuring of the health status of all
Europeans, the European Commission developed a
Healthy Life Years (HLY) indicator which is the part of
the family of DFLE, being based on a general activity limi-
tation indicator (GALI) [10], and introducing a concept of
quality of life [9]. The HLY was presented in the set of
structural indicators selected and defined to help measure
progress of the 2000 Lisbon strategy objectives [11].
Realising the importance of health as a determinant
and a driver of economic growth and competitiveness,
the European Commission decided to include public
health policy into its economic Lisbon Agenda [12].
HLY indicator was introduced to monitor health as an
economic/productivity and societal welfare factor [12].
The Europe 2020 strategy, a successor of the Lisbon
Strategy, therefore, highlights the ageing of the EU
population as one of pressing societal challenges, calling
for actions to foster active and healthy ageing. Health
and healthy population is fundamental to the pursuit
of smart, sustainable and inclusive growth and better
jobs [13].
In one of its flagship initiatives – Innovation Union -
Europe 2020 proposed launching a European Innovation
Partnership on Active and Healthy Ageing that aims to
address the challenge of ageing through innovation [14].
The Partnership sets a headline target to increase HLY
at birth on EU average by 2 years by 2020. It is an ambi-
tious yet firm health goal that strives to reduce the
socio-economic risks associated with demographic
change and to underpin quality of life of all Europeans
and especially the older Europeans.
The objective of this paper is to provide analytical re-
search that supported the European Commission in set-
ting the target of increasing healthy lifespan of
Europeans by 2 years by 2020. Similarly to life expect-
ancy projections predicting an increasing trend for thenext few decades, the paper explores the possible effect
of continually postponing death on the overall preva-
lence of morbidity and disability. It explores three sce-
narios of HLY trends - compression of morbidity,
expansion of morbidity, intermediary dynamic equilib-
rium - which give a range of possible values to be
achieved by 2020 on the basis of which the Partnership
selected the goal to be pursued.
The first scenario, proposed by Fries [15,16] assumes
that life expectancy is reaching its limit, and the period
of ill-health and disability before death is shortened. This
theory has two parts: delays in the onset of chronic dis-
ease/disability in later life, and one stage in the progres-
sion of chronic disease [17]. Accordingly, morbidity and
disability are gradually compressed into the shorter span
between the increasing age at onset of morbidity and the
age at death, and the number of years spent with dis-
eases or disability decreases over time.
The expansion of morbidity hypothesis, developed by
Gruenberg and Kramer [18,19] states that mortality
reductions will produce more years with morbidity and
related disability. The decline in mortality is largely due
to the decreasing fatality rate of diseases, rather than a
reduction in their incidence. The final stage of the pro-
gress of fatal chronic disease is delayed and mainly due
to life-sustaining medical interventions. Consequently,
declining mortality from fatal diseases does expand lon-
gevity but with a substantial increase in the population
at high risk of chronic morbidity and related disability.
This induces a shift in the distribution of causes of dis-
ability from fatal toward less fatal or nonfatal diseases.
This alternative intermediate hypothesis, suggested by
Manton [20], states that there exists equilibrium be-
tween life expectancy and the health and functioning of
the elderly population. In this scenario increased survival
does produce an increase in years with morbidity, but
years with severe morbidity and disability are relatively
constant, because the pace of progression of chronic dis-
eases and disability is reduced. In other words, the pro-
portion of a life span lived with serious illness or
disability decreases, whereas the proportion with
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declines in the rate of disease progression delay the
onset of more serious disease states, the dynamic equi-
librium scenario implies that mortality reductions will
be associated with a redistribution of disease and disabil-
ity from more to less severe states [5].
The paper does not aim to present complex methodo-
logical prediction models. It rather produces a straight-
forward analysis of HLY projections that helped the
European Commission set a firm, politically sound, tar-
get. In order to reach that goal, policy makers need to
commit to redefining health priorities and goals and




At the time of drafting the paper, the most recent avail-
able data for HLY was from 2008, expect for Belgium,
Italy and the UK that provided only data for 2007. 2008
thus is a baseline year for the analysis.
Data on life expectancy (LE) at birth for males and
females in 2008 for each Member State were obtained
from Eurostat [21]. The projected changes in life expect-
ancy at birth for males and females between 2009 and
2020 were drawn from Eurostat Population Projections
2010-based EUROPOP2010 [22].
Data on healthy life years (HLY) at birth by age, for
each Member State and EU27, were drawn from Euro-
stat [23] that uses the standard Sullivan method for HLY
calculation [24]. The prevalence of the health status
under consideration in each age group divides the num-
ber of person-years into years lived with this status [25].
HLY is based on a Global Activity Limitation Indicator
(GALI) question that is a component of the Minimum
European Health Module, included in the European
Union Statistics of Income and Living Conditions Survey
(EU-SILC) [26,27]. The survey is organized by Eurostat.
HLY thus becomes a strong indicator allowing for the ef-
fective monitoring of levels of health within and between
all EU countries in a comparable and consistent way
[28]. HLY in comparison to other health expectancy
indicators defines healthy condition by the absence of
limitations in functioning/disability while explicitly using
different levels of health status. Thus it views the health
positively [29].
Methods and calculations
Computations of HLY projections up to 2020 were esti-
mated under three broad scenarios for future health sta-
tus of the population: (1) the compression of morbidity,
(2) the expansion of morbidity, and (3) the intermediary
dynamic equilibrium. These drew on theories, as
explained above, based on the extent to which healthstatus (or morbidity/disability) of the population may
change over time in relation to the growing life expect-
ancy. The scenarios differ in terms of the expected size
of the increase in life expectancy and the way in which
these mortality reductions might be achieved. For each
one a set of assumptions was developed. In all of them,
life expectancy was expected to increase according to
Eurostat projections. Additionally Scenario 1 assumed
that by 2020 HLY would increase by at least the same
nominal value as life expectancy and that an increase in
life expectancy would be 100% healthy. Scenario 2
assumed that remaining HLY would remain the same for
the projected period, and all increase in life expectancy
would be 100% with activity limitations. Scenario 3 con-
sidered that HLY/LE ratio would remain the same and
that not every increase in life expectancy would be
healthy.
The analysis is simplified to basic formulas based on
data available for LE and HLY. Values for both LE and
HLY available on Eurostat – due to data gaps – often
limit to individual MSs and rarely provide EU27 average
values. Projections of LE referred to individual member
states. Therefore EU27 average values of future LE and
HLY were computed.
Results
Life expectancy (LE) at birth has been increasing since
decades for both males and females in the EU27. In
2008, the EU27 average LE at birth was estimated to be
74.9 years for males and 81.4 years for females (Table 1).
Further gains are projected mostly from lower mortality
at older ages. Increasing trends of life expectancy do not
however pre-empt a healthy longevity. In 2008 on EU27
average healthy life years (HLY) at birth was estimated
as 60.6 years for men and 61.8 years for women (Table 1).
The significant gap between HLY and LE exist among all
Member States (MSs) for both men and women - in
2008 14.4 years for men and 19.6 for women - as shown
in Figures 1 and 2. The healthy years represented around
81% and 76% of the total life expectancy at birth for
men and women respectively (Table 1). Values for LE
and HLY at birth showed significant differences among
Member States, however the spread of HLY at birth was
much greater than of LE, observing a gap of nearly 18
years for men and 20 years for women (Table 2).
Such inter-country differences in values of LE and
HLY across the EU make it difficult to model any EU
level projections.
Compression of morbidity
Under this scenario, the study predicted that life expect-
ancy and HLYs for men would grow on average at nearly
same 2-year pace by 2020 (Table 1). For women, LE and
HLYs would increase on average by 1.6 and 1.4 years
Table 1 Life expectancy and healthy life years at birth within the European Union, 2008 and projections under
different scenarios for 2020
Males 2008 2020 Difference 2008-2020
LE HLY HLY/LE% LE HLY HLY/LE% LE HLY* HLY/LE%**
Compression 74.9 60.6 80.8 77.0 62.6 81.3 2.1 2.0 0.5
Expansion 74.9 60.6 80.8 77.0 60.6 78.6 2.1 0.0 −2.2
Dynamic Eq 74.9 60.6 80.8 77.0 62.2 80.9 2.1 1.6 0.1
Females 2008 2020 Difference 2008-2020
LE HLY* HLY/LE% LE HLY HLY/LE% LE HLY* HLY/LE%**
Compression 81.4 61.8 75.9 83.0 63.2 76.4 1.6 1.4 0.5
Expansion 81.4 61.8 75.9 83.0 61.8 74.5 1.6 0.0 −1.4
Dynamic Eq 81.4 61.8 75.9 83.0 63.0 75.9 1.6 1.2 0.0
EU average values of LE and HLY = simple mean of values of 27 EU members (2007 values for IT, BE and UK).
*Difference in the HLY: gain/loss of number of years spent healthy.
**Difference in the HLY/LE ratio: gain/loss in the proportion of remaining life spent healthy (HLY/LE%).
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would remain unchanged (14.4 years for men; 19.8 years
for women by 2020). The HLY/LE ratio would improve
from 80.8% to 81.3% for men and from 75.9% to 76.4%
for women. In relative terms (HLY/LE%), the remaining
healthy lifespan would increase only by 0.5% for both
men and women. This scenario foresees a very slight re-
duction of health inequalities among the MSs, namely
the HLY gap, which is defined as the difference between
the highest and lowest HLY, would decrease by 1.4 years
for men and by 1.2 years for women, reaching 16.3 years
and 18.4 years respectively (Table 2).
Expansion of morbidity
Similar to the previous scenario, life expectancy would
increase by 2.1 years and 1.6 years for men and women
respectively by 2020, while HLYs would remain un-
changed (Table 1). The expansion of morbidity would
imply an increase in the expected years with disability of
2.1 years in men and 1.6 years in women. This would re-
sult in a deterioration of the HLY/LE ratio for both menTable 2 Health inequalities between Member States within th
different scenarios for 2020
Males 2008
HLY gap Lowest HLY Highest HLY HLY
Compression 17.7 51.5 LV 69.2 SE 16.3
Expansion 17.7 51.5 LV 69.2 SE 17.7
Dynamic Eq 17.7 51.5 LV 69.2 SE 16.8
Females 2008
HLY gap Lowest HLY Highest HLY HLY
Compression 19.6 52.3 SK 71.9 MT 18.4
Expansion 19.6 52.3 SK 71.9 MT 19.6
Dynamic Eq 19.6 52.3 SK 71.9 MT 18.9
LV Latvia, SE Sweden, SK Slovakia, MT Malta, LU Luxembourg.and women from 80.8% to 78.6% and from 75.9% to
74.5% respectively. The proportion of life in good health
would be reduced: 2.2% and 1.4% loss of good health for
men and women respectively. This scenario would not
change the level of health inequalities among Member
States, remaining a gap of 17.7 years for men and 19.6
years for women (Table 2).Dynamic equilibrium
Under this scenario, HLY at birth on EU average is
expected to increase by 2020 but to a lesser extent as
the rise in life expectancy, namely by 1.6 years in men
1.2 years in women (Table 1). This would imply that
HLY/LE ratio would remain unchanged for women while
would increase by 0.1% for men, and in relative terms
this would mean nearly no improvement in healthy life
expectancy by 2020. Health inequalities in men would
be reduced by 0.9 years, reaching 16.8 years, while in
women would increase by 0.7 years, reaching 18.9 years
(Table 2).e EU measured by HLY gap, 2008 and projections under
2020 Difference 2008-2020
gap Lowest HLY Highest HLY HLY gap
54.3 LU 70.6 SE −1.4
51.5 LV 69.2 SE 0.0
53.6 LU 70.4 SE −0.9
2020 Difference 2008-2020
gap Lowest HLY Highest HLY HLY gap
54.3 SK 72.7 MT −1.2
52.3 SK 71.9 MT 0.0
53.6 SK 72.5 MT −0.7
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Increasing trends in longevity and uncertainty in the de-
velopment of HLY across the EU countries raise the
question of whether people will live longer and healthier
lives, longer but more disabled lives, or something in be-
tween. To challenge this query, the study computed fu-
ture HLY at birth for the EU27 as whole, based on
calculations for individual MSs, under 3 scenarios. This
scenario modelling allowed to observe the interplay of
changes in mortality and morbidity and disability trends,
and to determine whether population health is to im-
prove or deteriorate.
Predictions about the likely effect of the continually
delaying death on the period of morbidity and disability
at the end of life depend on the causal factors that are
driving this trend. As previously emphasised, data limita-
tions make confident interpretation of past trends nearly
impossible, thus hindering the robust computing of fu-
ture scenarios. This means a great level of uncertainty
for predicting which scenario might prevail. Difficulties
in forecasting the development of health expectancies
(here HLY) reinforce the conclusions of other studies
which contend that gaps in existing health data impede
the modelling on the basis of the past trends of health
status and health expectancy [5]. This makes it diffi-
cult to establish any coherent set of hypotheses for
projections of health status [5]. In addition, other
factors that might influence the health of future
cohorts (e.g. changes in life style such as higher
obesity levels or the opportunity to introduce new
medical technologies) were not considered in the study
despite the fact that these factors would affect the predicted
HLY under the different scenarios.
Compression of morbidity
The results of this scenario illustrated the future poten-
tial for health improvement from policies that increase
healthy life years. Areas of intervention, that are covered
by the Partnership, should include preventive strategies
for healthy or healthier lifestyles and preventive mea-
sures to combat chronic diseases postponing the onsetFigure 3 Scenarios for the future male population health by Healthyof age-associated diseases, and allowing for an entire
plausibility of the compression of morbidity scenario.
Expansion of morbidity
This scenario’s outcomes presented the potential of
medical and care advances in reducing fatality rates for
chronic diseases while holding disease incidence and
underlying patterns of the disease constant. This results
in a longer survival with advanced degenerative and dis-
abling diseases so that the period of time that people
spend in a state of chronic ill-health and disability at the
end of the life increases. An increase in life expectancy,
in this case mainly driven by the growing and innovative
capabilities of medicine and care to prevent fatal out-
comes from degenerative diseases, creates pressure on
health and social care services. It is also a burden on
carers and communities, as greater numbers suffer
chronic disease and disability.
Dynamic equilibrium
The outcomes envisaged under this hypothesis in terms
of an increase in life expectancy as well as better health
would be possible if medical interventions and advances
as well as lifestyle changes were put in place in an earlier
(less severe) stage of the disease process. Consequently,
due to improved secondary prevention, among others,
long term social care costs would not have to experience
greater pressure.
Figures 3 and 4 summarise the analysis of the 3 sce-
narios, illustrating the direction of expected change of
healthy life years over the next 10 years. The plausibility
in achieving the target of improved lives spent in good
health under 2 scenarios - the compression of morbidity
and the dynamic equilibrium - can be clearly depicted.
These two scenarios predict an increase of HLY at EU
average level by 1.6 to 2 years for men and 1.2 to 1.4
years for women This is however, under the condition
that relevant policy intervention and action, including
health promotion and preventive action and the use of
medical and care advances, is implemented. Also, het-
erogeneity of developments of HLY among individualLife Years (HLY) in the European Union, 2009-2020.
Figure 4 Scenarios for the future female population health by Healthy Life Years (HLY) in the European Union, 2009-2020.
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setting of relevant policy measures.
The results of the study triggered the political decision
of setting the global target of 2 additional HLY for the
European Innovation Partnership on Active and Healthy
Ageing to be achieved within a decade.
Conclusions
The analysis needs to be considered with a high level of
prudence and bearing in mind a margin of error. A
series of other factors, as mentioned above, exist that
might impact people’s life expectancies, mortality and
morbidity rates and have not been considered.
Following results observed under the different scenar-
ios (Table 1), the potential HLY target could foresee an
increase by 2 years for men and 1.4 years for women at
the EU level. It is a ‘grand’ goal but can be reached in
next couple of years.
However, the big challenge is how to reflect MS levels
of health development in the EU average health indica-
tor. Statistics clearly show that EU countries characterise
very different levels of health progress, with a gap of 2
decades and diverging trends. With this in mind, the EU
HLY target should be complemented by national HLY
targets for men and women, set by MSs. It would make
MSs feel equally responsible for the delivery of the HLY
target, regardless of their starting positions. In addition,
accompanying the EU headline target with national tar-
gets would be in line with the Europe 2020 approach
breaking with ‘one size fits all’ approach.
There is an urgent need for action and intervention at
different levels in order to close a gap between a number
of life years and those lived in good health, disability or
frailty free.
It should be nevertheless emphasized that the identifi-
cation of HLY as a headline target for one of Europe
2020 key initiatives is a move forward towards develop-
ment of comparable, robust and sustainable health indi-
cators. Given the multifaceted goals of the Partnership
aiming to improve not only health status but also quality
of life, this initiative is a great opportunity to develop acomprehensive monitoring framework based on a set of
indicators that monitor health, quality of life, while sup-
porting active ageing and employment in the context of
lengthening of life, with sound and comparable, less sub-
jective data.
In conclusion, the HLY indicator offers the means to
monitor whether and to what extent the reduction of
the longevity gaps in the EU and the increase in life ex-
pectancy impact better functional health and better
quality of life. HLY developments can also support in
setting up adequate policy measures helping to compress
health expectancy gaps across EU countries and between
genders [3,30].
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